Developmental determinants in non-communicable chronic diseases and ageing

J Bousquet, Jm Anto, K Berkouk, P Gergen, J Pinto Antunes, P Augé, T Camuzat, J. Bringer, Jacques Mercier, N Best, et al.

To cite this version:

J Bousquet, Jm Anto, K Berkouk, P Gergen, J Pinto Antunes, et al.. Developmental determinants in non-communicable chronic diseases and ageing. Thorax, BMJ Publishing Group, 2015, 70 (6), pp.595-597. 10.1136/thoraxjnl-2014-206304. hal-01263281

HAL Id: hal-01263281
https://hal.archives-ouvertes.fr/hal-01263281
Submitted on 21 Jan 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
AUDIT, RESEARCH AND GUIDELINE UPDATE

Developmental determinants in non-communicable chronic diseases and ageing


ABSTRACT

Prenatal and peri-natal events play a fundamental role in health, development of diseases and ageing (Developmental Origins of Health and Disease (DOHaD)). Research on the determinants of active and healthy ageing is a priority to: (i) inform strategies for reducing societal and individual costs of an ageing population and (ii) develop effective novel prevention strategies. It is important to compare the trajectories of respiratory diseases with those of other chronic diseases.

Prenatal and peri-natal events play a fundamental role in health, development of diseases and ageing (Developmental Origins of Health and Disease (DOHaD)). Research on the determinants of active and healthy ageing (AHA) is a priority to: (i) inform strategies for reducing societal and individual costs of an ageing population and (ii) develop effective novel prevention strategies.

The European Union (EU) leads a global effort to understand the early determinants of ageing. The Polish Presidency of the EU Council (2011) targeted chronic respiratory diseases in children to promote AHA.1 The developmental determinants of chronic diseases in ageing were reinforced during the Cyprus Presidency of the EU Council (2012). Several projects of the EU Sixth and Seventh Framework Programme for Research and Technological Development (FP6 and FP7) were funded to understand the mechanisms of prenatal and early life events on the development of chronic diseases. One of the action plans of the European Innovation Partnership on AHA is devoted to integrated care for chronic diseases, and chronic respiratory diseases have been selected as the model for chronic diseases.

As part of this research initiative, a meeting in Montpellier on 2 and 3 December 2013 attempted to better understand the early life events that may impact ageing in health and disease, with a particular focus on respiratory diseases. The results of the FP6 and FP7 projects on population-based cohorts in adults and old age were reviewed to propose novel research, policies and value creation. The full report is in the online supplement and on the MACVIA-LR website (macvia.crlanguedocroussillon.fr).

IMPOR TANCE OF LIFE COURSE MODELS TO UNDERSTAND HEALTHY AGEING AND DISEASE

Biological ageing is the progressive deterioration of function that occurs in the postmaturity phase and can be assessed at the individual, physiological systems and cellular levels.2 Cross cohort comparisons of British birth cohorts show that social and biological factors from early life onwards can affect ageing, in particular respiratory function and disease.

In order to detect health-promoting factors, the early life events of diseases such as COPD need to be understood (European COST action BM1201: Developmental Origins of Chronic Respiratory Disease3). Susceptibility to COPD is associated with markers of foetal growth and early childhood disadvantage. Lung function at birth is determined by in utero processes.

Future research needs to develop a life course model of ageing that integrates the rather separate research on specific diseases or clinical conditions, functional ageing and well-being and should include socio-economic characteristics.

BIRTH COHORTS FOCUSING ON CHRONIC RESPIRATORY DISEASES IN THE GENERAL POPULATION

Asthma and allergic diseases begin early in life. Birth cohort studies are relevant to investigate environmental and lifestyle determinants of asthma and IgE-associated diseases or the absence of such
diseases. Over 30 community-based birth cohorts focusing on asthma and allergies have started in Europe and many have been pooled. The Network of Excellence GA²LEN (FP6, contract No FOOD-CT-2004-506378) has initiated birth cohort harmonisation. Two concerted actions, CHICOS (FP7 No. 241604) and ENRIECO (FP7 grant agreement No 226285), have built a network of more than 70 birth cohorts across Europe. Mechanisms of the Development of ALLergy (MeDALL, FP7 No. 261357) attempts to generate novel knowledge on the mechanisms of allergy onset and proposes early diagnosis, prevention and targets for therapy based on a new standardised follow-up of birth cohorts in Europe.

Numerous cohort studies have shown that early decrements in spirometry persist into late middle age, underscoring the crucial importance of early life influences. Optimal lung development depends on normal airway function at birth as well as normal growth during childhood up to the plateau of spirometric function around 25 years of age. After this, lung function declines as a normal event.

The geographical and temporal diversities of birth cohorts in MeDALL provide an excellent opportunity to study the effects of living conditions in different places since these are likely to be major determinants in the causation of the wave of chronic diseases currently observed.

An NIAID, NHLBI and MeDALL joint workshop (September 2012) identified over 60 birth cohorts focusing on asthma and allergy worldwide in order to (i) document the knowledge obtained, (ii) identify the knowledge gaps and inconsistencies and (iii) develop strategies for moving forward. Following the workshop in 2012, an online database containing information about existing cohorts was created to facilitate collaboration (AsthmaBirthCohorts.niaid.nih.gov).

Some population-based birth cohorts (PIAMA, BAMSE, ECA, MAS) have information on chronic diseases and their risk factors and can assess chronic diseases and AHA across the life cycle.

NUTRITION, OBESITY AND DIABETES ACROSS THE LIFE COURSE

Chronic diseases often start early in life and their processes expand over the life course. DORIAN (Developmental ORigins of healthy and unhealthy AgeNing: The Role of Maternal Obesity, FP7) aims at linking studies of early developmental processes with those of ageing from a life course perspective.

A better knowledge on the developmental origin of obesity and type-2 diabetes may lead to preventive measures in order to reduce the global epidemic of these two diseases.

Nutrition is vital for health and disease prevention. The Supplementation with Antioxidant Vitamins and Minerals (SU.VI.MAX) study was a controlled trial (12 741 persons) followed up for 8 years (1994–2002) to test the efficacy of dietary manipulations in lowering the incidence of chronic diseases and cancer. No supplementation was administered to participants in SU.VI.MAX 2. Food intake and nutritional factors in infancy and childhood have also been studied in several of the ongoing European birth cohorts, which allows for unique longitudinal association analyses on various chronic diseases.

Nutrition is vital to understand the development of chronic diseases and the promotion of healthy ageing.

ADULT COHORTS IN CHRONIC DISEASES

The French prospective cohort (E3N), the EPIC-France cohort, is composed of women who were under a health insurance plan, the Mutuelle Générale de l’Education Nationale, for schoolteachers and coworkers. In 1990, about 100 000 women (40–65 years) were recruited. Epidemiological research in nutrition, hormones and chronic diseases (asthma, diabetes or osteoporosis) studied the risk factors for developing these diseases.

Two large European epidemiological cohorts, recruited in the early 1990s and followed up for 20 years, have been carried out in respiratory health: (i) the European Community Respiratory Health Survey (ECRHS; http://www.ecrhs.org/), including 18 668 individuals aged 20–44 years at baseline and (ii) the Epidemiological study of the Genetics and Environment of Asthma, bronchial hyperresponsiveness and atopy (EGEA; http://geeanet.yfj.inserm.fr), a French case-control and family study of adults and children at baseline, including 2120 individuals aged 7–70 years at baseline. Combined analyses between these cohorts have been performed.

COPACETIC, a cohort of the lung cancer screening trial with over 2200 individuals with lung function and CT scans, identified genes associated with lung function decline in interaction with smoking, CT scan-based emphysema and coronary calcifications.

LifeLines (The Netherlands) is a three-generation cohort of 165 000 individuals followed annually by questionnaire and, every 5 years, by extensive functional screening of the five prime research areas: (1) metabolic/hormonal, (2) heart/vessel/kidney, (3) lung/respiratory/allergy, (4) psychiatric and (5) musculoskeletal.

Old age cohorts include participants that have been followed up for a long period of time, and may be used to link the development of factor profiles of chronic diseases from early life.

OLD AGE COHORTS

Neuropsychiatric disorders of old-age (eg, depression, Alzheimer’s disease) may be determined by earlier risk exposure. The DEVELAGE consortium (FP7) aims to characterise shared molecular pathways between the early developmental processes in the brain and brain ageing.

This example underlines the limits of old age cohorts in the study of chronic neuropsychiatric disorder in the elderly.

Integrated research on DDevelopmental determinants of Ageing and Longevity (IDEAL; http://www.ideal-ageing.eu, FP7) examines the role of epigenetic regulation and transmission to next generations. A unique human cohort and animal studies are studied to discover novel longevity pathways and the links between development and ageing.

The Three-City Study (3C Study) is a population-based longitudinal study of the relation between vascular diseases and dementia in persons aged 65 years and older. A total of 9294 participants of both sexes were recruited from three French cities. CONSTANCES, a large general-purpose epidemiological population-based cohort, aims to provide public health information. The cohort is a representative sample of 200 000 French adults, aged 18–69 years at inception.
Cohorts in middle and old age adults can be intertwined with earlier cohorts to understand the mechanisms of AHA and diseases in ageing.

Recommendations for future research are reported in the online supplement and the MACVIA-LR website on (i) integration of omics in epidemiological studies across the life cycle, (ii) performance of longitudinal studies assessing chronic diseases and (iii) value of European birth cohorts to study chronic diseases and AHA. Cohorts with an initial focus on chronic respiratory diseases could be expanded to understand the trajectories of chronic diseases and AHA.

Cohorts across the life cycle are essential to understand AHA. Lifelong birth cohorts give an overview of the problem and are complemented by cohorts carried out at different ages. Birth cohorts initially focusing on chronic respiratory diseases offer highly valuable additive information to understand chronic diseases and AHA.

Author affiliations
1University Hospital, Montpellier, France
2Inserm U 1168, Paris, France
3Contes les Maladies Chroniques pour un Veillissement Actif en Languedoc Roussillon, Site de Référence de l’EIP on AHA, Montpellier, France
4MeDALL, Mechanisms of the Development of Allergy, FF7, Amsterdam, Groningen, the Netherlands
5Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain
6IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
7Universitat Pompeu Fabra (UPF), Barcelona, Spain
8CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain
9Deputy Head of Unit for Medical Research and the Challenge of Ageing, DG Research & Innovation, European Commission, Brussels, Belgium
10National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA
11European Commission, Directorate General for Health and Consumers, Brussels, Belgium
12University Montpellier 1, France
13Région Languedoc Roussillon, France
14Montpellier Medical School, France
15Department of Physiology, Montpellier University Hospital, France
16University Montpellier 1, France
17Nîmes University Hospital, France
18Montpellier University Hospital, France
19Swiss Institute of Allergy and Asthma Research (SIAF), Davos and University of Zurich, Switzerland
20David Hide Asthma and Allergy Research Centre, Isle of Wight, UK
21Inserm, Research Unit U1061, University Montpellier I, Montpellier, France
22Department of Paediatric Respiratory Medicine, Royal Brompton Hospital and National Heart and Lung Institute, Imperial College, London, UK
23Institute of Human Genetics, CNRS, Montpellier, France
24Equipe 10 UMR Inserm-Université Paris-Sud (Centre de recherche en Épidémiologie et Santé des Populations, CESP), Villejuif, France
25Nutrition, Hormones and Women’s Health Team, INSERM UMR-S 1018, Paris-South University, Villejuif, France
26Obesity Prevention Program, Department of Population Medicine, Harvard Medical School/Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA
27Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts, USA
28Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, and Harvard School of Public Health, UK
29Population-Based Epidemiological Cohorts, INSERM-UVSQ UMS O11, Villejuif, France
30Human Development & Health, Faculty of Medicine, University of Southampton, Southampton, UK
31Institute of Clinical Physiology, National Research Council (CNR), Pisa, Italy
32Horba, Montpellier, France
33Department of Geriatrics, University Hospital, Montpellier, France
34CEPS—Team of Respiratory and Environmental Epidemiology INSERM UMR-S 1018, University Paris-Sud, Villejuif, France
35Institute of Social Medicine, Epidemiology and Health Economics, Charité—Universitätsmedizin, Berlin, Germany
36Institute for Clinical Epidemiology and Biometry, Julius Maximilian University of Wuerzburg, Germany
37Department of Pediatric Pulmonology and Pediatric Allergology, University of Groningen, University Medical Center Groningen, Beatrix Children’s Hospital, Groningen Research Institute for Asthma and COPD, Groningen, The Netherlands
38Comprehensive Pneumology Center, Ludwig Maximilians University and Helmholtz Zentrum Muenchen, Member of the German Research Center for Lung Research, Großhadern, Germany
39MIRC Unit for Lifelong Health and Ageing at UCL, London, UK
40Institut de Médecine Régénératrice et de Biothérapie (I.M.R.B.), University Hospital, INSERM U1040, Montpellier, France
41Department of Paediatrics, University of Oslo and Oslo University Hospital, Oslo, Norway
42Bioclinica Informatics AG, Planegg, Germany
43Institute of Environmental Medicine, Karolinska Institutet and Sachs’ Children’s Hospital, Stockholm, Sweden
44Aix-Marseille University (AMU), Research Unit 912 AMU/INSERMIRD Social and Economic Sciences Applied to Health (SEESIM), France
45Department of Public Health and biostatistics, Descartes University, Paris, France
46Municipal Department of social action, childhood, and health, Paris, France
47SATT AxlR, Montpellier, France
48Department of Pulmonology, University Medical Center Groningen, University of Groningen, GRIAC Research Institute, Groningen, The Netherlands
49Inserm U1061 Neuropsychiatry, Montpellier and Faculty of Medicine, Imperial College London, London, UK
50Inserm Research Unit 988, Paris, France
51Inserm Research Unit 710, Montpellier, France
52Ecole Pratique des Hautes Etudes (EPHE), Paris, France
53Department of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw, Warsaw, Poland
54Team of Environmental Epidemiology applied to Reproduction and Respiratory Health, University Grenoble Alpes, IAB, Grenoble, France
55Team of Environmental Epidemiology applied to Reproduction and Respiratory Health, INSERM, IAB, Grenoble, France
56Team of Environmental Epidemiology applied to Reproduction and Respiratory Health, CHU de Grenoble, IAB, Grenoble, France
57Section of Molecular Epidemiology, Leiden University Medical Center, Leiden, the Netherlands
58Consortium for Healthy Aging, Leiden University Medical Center, Leiden, the Netherlands
59Julius Center of Health Sciences and Primary Care, University Medical Center Utrecht, University of Utrecht, Utrecht, the Netherlands
60Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
61University Hospital and INSERM U 1058, Montpellier, France
62EPHE, Section des Sciences de la Vie et de la Terre, Paris, France
63UMR 5 710, University Montpellier 2, Montpellier, Paris, France
64Institut Transdisciplinaire d’Études du Vieillissement, Montpellier, France
65Cyprus International Institute for Environmental & Public Health in Association with Harvard School of Public Health, Cyprus University of Technology, Limassol, Cyprus
66Director of Population-Based Epidemiological Cohorts, INSERM-UVSQ UMS O11, Villejuif, France

Contributors All authors participated to the meeting and contributed to the discussion.

Funding The meeting was supported by an unrestricted educational grant from the Région Languedoc Roussillon awarded by Mr. C Bourquin (President).

Competing interests None.

Provenance and peer review Not commissioned; internally peer reviewed.

REFERENCES